» Articles » PMID: 30444433

Health-related Quality of Life in Adult Primary Immune Thrombocytopenia

Overview
Specialty Hematology
Date 2018 Nov 17
PMID 30444433
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

: Immune thrombocytopenia (ITP) and the associated biologic and psychological effects can lead to reduced health-related quality of life (HRQoL). : This review focuses on the impact of ITP itself and its treatment on patients' HRQoL. The findings show that the HRQoL is uniformly reduced amongst ITP patients, both with and without interventions. ITP significantly affects many aspects of patient HRQoL, which is comparable to that of patients with other chronic diseases. However, there is a lack of longitudinal studies among unselected ITP populations and the majority of studies focus on statistical differences between groups or between measures at different time points rather than quality of life (QoL) changes that are perceived as clinically relevant in patients. : Due to ITP being a chronic disease with an ongoing risk of bleeding, many treatments, and a good prognosis for survival, patients deal with their symptoms over prolonged time periods and good HRQoL is very important. In this review of HRQoL in ITP, we provide data on the current understanding, how HRQoL may be modified by treatment, and why it needs to be included as an outcome in future studies to optimize management of HRQoL issues in clinical practice.

Citing Articles

Health-related quality of life and complications of corticosteroid treatment in patients with immune thrombocytopenia in two teaching hospitals in Ethiopia: a cross-sectional study.

Beyene D, Sisay E, Fentie A, Gebremedhin A Front Med (Lausanne). 2024; 11:1423161.

PMID: 39564500 PMC: 11573527. DOI: 10.3389/fmed.2024.1423161.


Mental health and use of psychotropic prescription drugs in adult patients with primary immune thrombocytopenia: a nationwide population-based cohort study.

Mannering N, Hansen D, Pottegard A, Andersen K, Frederiksen H Haematologica. 2024; 109(9):2944-2954.

PMID: 38721747 PMC: 11367223. DOI: 10.3324/haematol.2024.285364.


Burden of immune thrombocytopenia (ITP): Special considerations for refractory ITP.

Rufer A, Terrell D Br J Haematol. 2023; 203(1):79-85.

PMID: 37735553 PMC: 11847310. DOI: 10.1111/bjh.19068.


Safety of non‑peptide thrombopoietin receptor agonists in patients with immune thrombocytopenia: A systematic review and meta‑analysis of short‑term double‑blind randomized clinical trials.

Shen N, Qiao J, Jiang Y, Yin H, Li M, Zhu S Exp Ther Med. 2023; 26(2):393.

PMID: 37456173 PMC: 10347292. DOI: 10.3892/etm.2023.12092.


Survival in adult patients with chronic primary and secondary immune thrombocytopenia: A population-based study.

Mannering N, Hansen D, Pottegard A, Frederiksen H Transfusion. 2023; 63(2):415-426.

PMID: 36601709 PMC: 10108240. DOI: 10.1111/trf.17212.